Castration resistance is in part attributable to aberrant activation of androgen receptor (AR)
signaling by the intracrine activation of androgen precursors derived from adrenal glands …

While androgen deprivation therapy (ADT) remains the primary treatment for metastatic
prostate cancer (PCa) since the seminal recognition of the disease as androgen-dependent …

PURPOSE:: Androgen receptor signaling remains essential for many prostate cancers that
have progressed despite androgen deprivation therapy. After medical or surgical castration …

The decades-old terminology of androgen independence has been replaced in recent years
with castration-resistant prostate cancer. Biological and clinical evidence have together …

The survival and progression of prostate cancer are generally dependent on expression of
the androgen receptor (AR), as well as the availability of endogenous AR agonists …

Castration resistant prostate cancer (CRPC) remains androgen dependant despite castrate
levels of circulating testosterone following androgen deprivation therapy, the first line of …

Relapse of castration-resistant prostate cancer (CRPC) that occurs after androgen
deprivation therapy of primary prostate cancer can be mediated by reactivation of the …

The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in
prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth …

A significant proportion of castration-resistant prostate cancers (CRPC) remains driven by
ligand activation of the androgen receptor. Although the testes are the primary source of …

Androgens play an essential role in prostate cancer. Clinical treatments that target
steroidogenesis and the androgen receptor (AR) successfully postpone disease …